Analyst Coverage

A financial report for AroVella Therapeutics Ltd dated December 5, 2024, includes sections on cancer immunotherapy, company valuation, investment thesis, risks, and upcoming events, with charts, logos, and contact information.

MST ACCESS | CAR-iNKT, next gen cancer killer. Cutting-edge. Human trials start CY25. Undervalued.

A$0.34 valuation

December 2024
December 2024
Company financial report page showing Aroventa Therapeutics Ltd (ASX: ALA) stock details, market data, a stock chart, and a desk note discussing clinical trials, pipeline activities, and corporate strategy.

SPARK PLUS | Describes Arovella’s current product pipeline and its ambitions to tackle a range of blood cancers and solid tumours.

June 2024
June 2024